Advertisement

Topics

ChemDiv Heads Three-Way Development Agreement for Neurodegenerative Diseases

03:44 EST 15 Nov 2017 | Contract Pharma

Research will focus on Sigma1 dysfunction associated with early onset diseases, such as ALS and Alzheimer's

Original Article: ChemDiv Heads Three-Way Development Agreement for Neurodegenerative Diseases

NEXT ARTICLE

More From BioPortfolio on "ChemDiv Heads Three-Way Development Agreement for Neurodegenerative Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...